MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413028 | Name: Triamcinolone acetonide sodium Phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Triamcinolone acetonide sodium Phosphate is a Glucocorticoid

Chemical Structure

Triamcinolone acetonide sodium Phosphate
Triamcinolone acetonide sodium Phosphate
CAS#1997-15-5

Theoretical Analysis

MedKoo Cat#: 413028

Name: Triamcinolone acetonide sodium Phosphate

CAS#: 1997-15-5

Chemical Formula: C24H30FNa2O9P

Exact Mass: 558.1407

Molecular Weight: 558.45

Elemental Analysis: C, 51.62; H, 5.42; F, 3.40; Na, 8.23; O, 25.78; P, 5.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Triamcinolone acetonide sodium Phosphate; CL106359; CL-106359; CL 106359; CL61965; CL-61965; CL 61965
IUPAC/Chemical Name
Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-(phosphonooxy)-, disodium salt, (11beta,16alpha)-
InChi Key
XCMJCLDAGKYHPP-GKFFWNJRSA-L
InChi Code
InChI=1S/C24H32FO9P.2Na/c1-20(2)33-19-10-16-15-6-5-13-9-14(26)7-8-21(13,3)23(15,25)17(27)11-22(16,4)24(19,34-20)18(28)12-32-35(29,30)31;;/h7-9,15-17,19,27H,5-6,10-12H2,1-4H3,(H2,29,30,31);;/q;2*+1/p-2/t15-,16-,17-,19-,21-,22-,23-,24+;;/m0../s1
SMILES Code
C[C@@]12[C@@]3(C(COP([O-])([O-])=O)=O)[C@](OC(C)(O3)C)([H])C[C@@]1([H])[C@]4([H])CCC5=CC(C=C[C@]5(C)[C@@]4(F)[C@@H](O)C2)=O.[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 558.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;4:CD011993. doi: 10.1002/14651858.CD011993.pub2. PMID: 27115215. 2: Sharma A, Pirouzmanesh A, Patil J, Estrago-Franco MF, Zacharias LC, Pirouzmanesh A, Andley UP, Kenney MC, Kuppermann BD. Evaluation of the toxicity of triamcinolone acetonide and dexamethasone sodium phosphate on human lens epithelial cells (HLE B-3). J Ocul Pharmacol Ther. 2011 Jun;27(3):265-71. doi: 10.1089/jop.2010.0120. Epub 2011 May 16. PMID: 21574867. 3: Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R. Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment. Eur J Pharm Biopharm. 2011 Jun;78(2):271-7. doi: 10.1016/j.ejpb.2010.12.018. Epub 2010 Dec 21. PMID: 21172437. 4: Dragoo JL, Danial CM, Braun HJ, Pouliot MA, Kim HJ. The chondrotoxicity of single-dose corticosteroids. Knee Surg Sports Traumatol Arthrosc. 2012 Sep;20(9):1809-14. doi: 10.1007/s00167-011-1820-6. Epub 2011 Dec 21. PMID: 22186921. 5: Hwang H, Park J, Lee WK, Lee WH, Leigh JH, Lee JJ, Chung SG, Lim C, Park SJ, Kim K. Crystallization of Local Anesthetics When Mixed With Corticosteroid Solutions. Ann Rehabil Med. 2016 Feb;40(1):21-7. doi: 10.5535/arm.2016.40.1.21. Epub 2016 Feb 26. PMID: 26949665; PMCID: PMC4775754. 6: Ferguson AD, Emerson RM, English JS. Cross-reactivity patterns to budesonide. Contact Dermatitis. 2002 Dec;47(6):337-40. doi: 10.1034/j.1600-0536.2002.470604.x. PMID: 12581279. 7: Braun HJ, Wilcox-Fogel N, Kim HJ, Pouliot MA, Harris AH, Dragoo JL. The effect of local anesthetic and corticosteroid combinations on chondrocyte viability. Knee Surg Sports Traumatol Arthrosc. 2012 Sep;20(9):1689-95. doi: 10.1007/s00167-011-1728-1. Epub 2011 Oct 29. PMID: 22037813. 8: Derby R, Lee SH, Date ES, Lee JH, Lee CH. Size and aggregation of corticosteroids used for epidural injections. Pain Med. 2008 Mar;9(2):227-34. doi: 10.1111/j.1526-4637.2007.00341.x. PMID: 18298706. 9: Mahlberg K, Krootila K, Uusitalo R. Compatibility of corticosteroids and antibiotics in combination. J Cataract Refract Surg. 1997 Jul-Aug;23(6):878-82. doi: 10.1016/s0886-3350(97)80247-7. PMID: 9292672. 10: Saini JS, Gupta A, Pandey SK, Gupta V, Gupta P. Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis. Acta Ophthalmol Scand. 1999 Oct;77(5):515-8. doi: 10.1034/j.1600-0420.1999.770505.x. PMID: 10551290.